- Home
- NXTC vs SABS Comparison
NXTC vs SABS Comparison
Compare NXTC & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- SABS
- Stock Information
- Founded
- NXTC 2015
- SABS 2014
- Country
- NXTC United States
- SABS United States
- Employees
- NXTC N/A
- SABS N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- SABS Health Care
- Exchange
- NXTC Nasdaq
- SABS Nasdaq
- Market Cap
- NXTC 20.6M
- SABS 19.0M
- IPO Year
- NXTC 2019
- SABS N/A
- Fundamental
- Price
- NXTC $0.40
- SABS $1.25
- Analyst Decision
- NXTC Strong Buy
- SABS Strong Buy
- Analyst Count
- NXTC 2
- SABS 5
- Target Price
- NXTC $3.50
- SABS $11.40
- AVG Volume (30 Days)
- NXTC 99.1K
- SABS 38.1K
- Earning Date
- NXTC 03-06-2025
- SABS 05-19-2025
- Dividend Yield
- NXTC N/A
- SABS N/A
- EPS Growth
- NXTC N/A
- SABS N/A
- EPS
- NXTC N/A
- SABS N/A
- Revenue
- NXTC N/A
- SABS $1,322,410.00
- Revenue This Year
- NXTC N/A
- SABS N/A
- Revenue Next Year
- NXTC N/A
- SABS $25.00
- P/E Ratio
- NXTC N/A
- SABS N/A
- Revenue Growth
- NXTC N/A
- SABS N/A
- 52 Week Low
- NXTC $0.35
- SABS $1.11
- 52 Week High
- NXTC $2.49
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- NXTC 22.20
- SABS 31.17
- Support Level
- NXTC $0.49
- SABS $1.11
- Resistance Level
- NXTC $0.67
- SABS $1.80
- Average True Range (ATR)
- NXTC 0.09
- SABS 0.16
- MACD
- NXTC -0.02
- SABS -0.01
- Stochastic Oscillator
- NXTC 12.74
- SABS 18.42
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.